Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies (Anthracycline Chemotherapy) from the Cardio-Oncology Study Group of the Heart Failure Association…
Charlson Comorbidity Index predicts 10-year survival in patients with multiple comorbidities. Variable Points Age <50 years 0 50–59 years +1 60–69 years +2 70–79…
For Multiple Myeloma Diagnostic Criteria assessment necessary to provide selection of the appropriate criteria: Criteria (A) Clonal bone marrow plasma cells ≥10% or (B) biopsy-proven…
Revised Multiple Myeloma International Staging System (R-ISS) – prognostication tool for myeloma patients based on the genetics and other routinely used lab values in conjunction…
Multiple Myeloma International Staging System (ISS) prognosticates the severity of multiple myeloma based on routinely obtained lab values. Use only in patients recently diagnosed with…
IMPEDE score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulators. Individual Risk Factors Points Myeloma risk scores Points Positive Factors …
Karnofsky performance status scale determines ability of patient to tolerate chemotherapy. For patients ≥ 16 years old. Useful to use over time to track disease…
International Prognostic Score of thrombosis in World Health Organization – essential thrombocythemia (IPSET-thrombosis). IPSET-thrombosis model provides objective estimates of the probability of thrombotic events in…
Follicular Lymphoma International Prognostic Index (FLIPI) estimates overall survival based on clinical information. FLIPI is designed to be used in patients with follicular lymphoma and…
Groupe d’Etude des Lymphomes Folliculaires (GELF) Criteria determines if immediate therapy for follicular lymphoma is required. The criteria can help identify those patients with follicular…
